Alprazolam for depression

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Trials

Background:

• The 'off-label' use of alprazolam for depression lacks systematic evaluation.
• Understanding alprazolam's antidepressant efficacy is crucial for clinical practice.

Purpose of the Study:

• To assess the antidepressant effect, tolerability, and acceptability of alprazolam monotherapy.
• Comparison against placebo and conventional antidepressants in outpatients and primary care settings.

Main Methods:

• Systematic search of multiple databases (Cochrane Library, EMBASE, MEDLINE, PsycINFO) up to February 2012.
• Inclusion of randomized controlled trials (RCTs) comparing alprazolam with placebo or conventional antidepressants.
• Independent data extraction and risk of bias assessment by two reviewers.

Main Results:

• Alprazolam demonstrated a positive effect in reducing depressive symptoms compared to placebo (MD -5.34, NNTB 3).
• Effectiveness was comparable to conventional antidepressants on continuous depression measures (MD 0.25).
• Alprazolam showed less effect on dichotomized depression severity (RR 0.86) and fewer all-cause withdrawals than conventional antidepressants.

Conclusions:

• Alprazolam appears more effective than placebo and comparable to tricyclic antidepressants for short-term depression symptom reduction.
• Study quality was generally poor and heterogeneous, limiting confidence in findings.
• Caution is warranted due to benzodiazepine dependency potential, despite lower withdrawal rates compared to some antidepressants.